Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer

PURPOSE: The prevalence of BRCA½ mutations in germline DNA from unselected ovarian cancer patients is 11% to 15.3%. It is important to determine the frequency of somatic BRCA½ changes, given the sensitivity of BRCA-mutated cancers to poly (ADP ribose) polymerase-1 (PARP1) inhibitors and platinum ana...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hennessy, Bryan T.J., Timms, Kirsten M., Carey, Mark S., Gutin, Alexander, Meyer, Larissa A., Flake, Darl D., Abkevich, Victor, Potter, Jennifer, Pruss, Dmitry, Glenn, Pat, Li, Yang, Li, Jie, Gonzalez-Angulo, Ana Maria, McCune, Karen Smith, Markman, Maurie, Broaddus, Russell R., Lanchbury, Jerry S., Lu, Karen H., Mills, Gordon B.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2010
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917312/
https://ncbi.nlm.nih.gov/pubmed/20606085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.27.2997
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados